Abatacept in the long-term treatment of rheumatoid arthritis

    loading  Checking for direct PDF access through Ovid

Abstract

Evaluation of: Kremer JM, Russell AS, Emery P et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann. Rheum. Dis. 70(10), 1826–1830 (2011).

The last decade has been an era of exciting and innovative therapeutic targets in the treatment of moderate-to-severe rheumatoid arthritis. One such treatment that acts by disrupting T-cell activation is abatacept, which is currently used in patients who have had an inadequate clinical response to traditional disease-modifying drugs or anti-TNF therapies. As newer therapies emerge, issues that need addressing include: long-term drug tolerance, adverse events, sustained clinical response, prevention of progression in structural damage and retention rates. In this article we discuss a recently published paper by Kremer et al. that reported 3-year data on safety, efficacy and radiographic progression in patients enrolled in a clinical trial of abatacept, as well as the advantages and limitations of long-term extension studies.

Related Topics

    loading  Loading Related Articles